FIGURE 1.

Formulation screening by evaluating the MRI effect and gene silencing activity in vitro. (A) GARP iLNP formulations prepared with various molar ratios of iBL0104, D‐B(Gd), DSPC, cholesterol, and DSPE‐PEG‐cRGD. D‐B(Gd) is short for DTPA‐BSA (Gd). (B) The imaging effects of GAP iLNPs with different amounts of Gd agent. (C) Particle sizes of various GAP/siRNA and GARP/siRNA complexes as detected by DLS. (D and E) Relative PLK1 mRNA expression in HepG2‐luc cells after treated with GAP iLNPs (D) and GARP iLNPs (E), respectively. **P < 0.01; ***P < 0.001, ****P < 0.0001